A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: Results of a seer database analysis

Clinical Genitourinary Cancer

Volumn 11, Issue 3, 2013, Pages 303-310

  Nelson, Rebecca A ^a   Vogelzang, Nicholas ^b   Pal, Sumanta K ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Cytokine; Metastatic renal cell carcinoma; Older adults; Survival; Targeted therapy; Trends

Indexed keywords

CYTOKINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CYTOREDUCTIVE SURGERY; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PAPILLARY CARCINOMA; SEX DIFFERENCE;

CYTOKINE; METASTATIC RENAL CELL CARCINOMA; OLDER ADULTS; SURVIVAL; TARGETED THERAPY; TRENDS;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; NEPHRECTOMY; REGISTRIES; SEER PROGRAM; SURVIVAL; TREATMENT OUTCOME;

EID: 84883449574     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.04.011     Document Type: Article

References (21)

1. G. Fyfe, R.I. Fisher, S.A. Rosenberg Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 1995 688 696
2. R.J. Motzer, J. Bacik, B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
3. S.K. Pal, M. Kortylewski, H. Yu Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers Mol Cancer Ther 9 2010 3115 3125
4. Khambati H, Choueiri TK, Kollmannsberger CK, et al. Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population. Paper presented at: 2011 Genitourinary Cancers Symposium; February 17-19, 2011; Orlando, FL.
5. S.K. Pal, J. Hsu, S. Hsu Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma J Geriatric Oncol 2012 [Epub ahead of print]
6. D.F. McDermott, M.B. Atkins Interleukin-2 therapy of metastatic renal cell carcinoma - predictors of response Semin Oncol 33 2006 583 587
7. US Department of Health & Human Services Approval letter for sorafenib http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2005/ 021923ltr.pdf Accessed: March 24, 2010
8. D.F. McDermott, M.S. Ghebremichael, S. Signoretti The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC) J Clin Oncol 28 2010 4514
9. C. Porta, E. Calvo, M.A. Climent Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial Eur Urol 61 2012 826 833
10. R.M. Bukowski, W.M. Stadler, D.F. McDermott Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program Oncology 78 2010 340 347
11. D.Y.C. Heng, W. Xie, M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor Targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
12. D.Y.C. Heng, T.K. Choueiri, J.-L. Lee et al. An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials J Clin Oncol 30 suppl 2012 abstract 4536 http://www.asco.org Accessed: April 24, 2013
13. J.H. Ku, K.C. Moon, C. Kwak Disease-specific survival in patients with renal cell carcinoma: an audit of a large series from Korea Jpn J Clin Oncol 41 2011 110 114
14. J.F. Piccirillo, R.M. Tierney, I. Costas Prognostic importance of comorbidity in a hospital-based cancer registry JAMA 291 2004 2441 2447
15. R.J. Motzer, J. Bacik, M. Mazumdar Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience Clin Cancer Res 10 2004 6302S 6303S
16. D. Shek, B. Tomlinson, M. Brown Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients Clin Genitourin Cancer 10 2012 93 98
17. B. Shuch, J.N. Hofmann, M.J. Merino Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results Program Urol Oncol 2013 Feb 29 [E pub ahead of print]
18. J.B. Yu, C.P. Gross, L.D. Wilson NCI SEER public-use data: applications and limitations in oncology research Oncol (Williston Park) 23 2009 288 295
19. J.K. Kiecolt-Glaser, K.J. Preacher, R.C. MacCallum Chronic stress and age-related increases in the proinflammatory cytokine IL-6 Proc Natl Acad Sci U S A 100 2003 9090 9095
20. H.T. Tran, Y. Liu, A.J. Zurita Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials Lancet Oncol 13 2012 827 837
21. A. Hurria, C.T. Cirrincione, H.B. Muss Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401 J Clin Oncol 29 2011 1290 1296